A Maryland-based COVID-19 vaccine producer is expanding its late-stage Phase 3 clinical trial study to include children ages 12 to 17. Novavax, headquartered in Gaithersburg, will assess the safety and effectiveness of its protein-based immunization on up to 3,000 adolescents across the United States, the company said Monday. Participants in the study will be monitored for two years after the last injection.
Maryland-based Novavax phase 3 clinical trial expands to include children 12 to 17
May 4, 2021